利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.053 秒)

    ALVAC/FIV constructs
    34.
    发明授权
    ALVAC/FIV constructs 失效
    ALVAC / FIV构建体

    公开(公告)号：US07255862B1

    公开(公告)日：2007-08-14

    申请号：US08746668

    申请日：1996-11-14

    申请人： James Tartaglia ,  Enzo Paoletti

    发明人： James Tartaglia ,  Enzo Paoletti

    IPC分类号： A61K39/21

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/525 ,  C12N2710/24043 ,  C12N2740/15022

    摘要： Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment, attenuated recombinant viruses containing DNA encoding a feline immunodeficiency virus epitope such as an antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinants can be NYVAC or ALVAC recombinants. The DNA can encode at least one of: Env, Gag, Pol, or combinations thereof such as Gag and Pol or protease or Env, Gag and Pol or protease. The recombinants and gene products therefrom and antibodies generated by them have several preventive, therapeutic and diagnostic uses. DNA from the recombinants are useful as probes or, for generating PCR primers or for immunization. The immunogenicity and protective efficacy of immunization protocols involving ALVAC-FIV and priming with a recombinant canarypox virus ALVAC-FIV vaccine followed by a booster immunization with inactivated FIV-infected celled vaccine (ICV) was evaluated against FIV challenge in cats and the protocol was shown to effectively induce FIV-specific protective immune responses. Further, it was found that immunized cats were fully protected from an initial challenge with a slightly heterologous FIV strain (50CID50) and were partially protected from a second challenge with a distinctly heterologous FIV strain (75CID50) given eight months after the initial challenge without any intervening booster.

    摘要翻译： 披露并要求保护含有和表达慢病毒，逆转录病毒或免疫缺陷病毒DNA的重组体及其制备和使用方法。 在示例性实施方案中，公开并要求保护含有编码猫免疫缺陷病毒表位的DNA的减毒重组病毒，例如抗原，以及使用病毒的方法和组合物，来自其的表达产物和由病毒或表达产物产生的抗体。 重组体可以是NYVAC或ALVAC重组体。 DNA可编码以下至少一种：Env，Gag，Pol或其组合，例如Gag和Pol或蛋白酶或Env，Gag和Pol或蛋白酶。 其重组体和基因产物及其产生的抗体具有几种预防，治疗和诊断用途。 来自重组体的DNA可用作探针或用于产生PCR引物或用于免疫。 针对猫的FIV攻击评估了涉及ALVAC-FIV的免疫方案的免疫原性和保护功效，并用重组金丝雀痘病毒ALVAC-FIV疫苗引发疫苗，随后用灭活的FIV感染的细胞疫苗（ICV）进行加强免疫，并显示了该方案 有效诱导FIV特异性保护性免疫应答。 此外，发现免疫的猫被轻微异源FIV毒株（50CID 50）完全保护免受初次攻击，并且用明显的异源FIV毒株（75CID 50 ）在初次挑战后八个月，没有任何介入的助推器。

    Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
    36.
    发明授权
    Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation 失效
    使用重组病毒和亚基蛋白制备的针对病毒的丙酰甲病毒科的两步免疫程序

    公开(公告)号：US06180398B2

    公开(公告)日：2001-01-30

    申请号：US08679065

    申请日：1996-07-12

    申请人： Michel H. Klein ,  James Tartaglia ,  George A. Cates ,  Mary E. Ewasyshyn

    发明人： Michel H. Klein ,  James Tartaglia ,  George A. Cates ,  Mary E. Ewasyshyn

    IPC分类号： C12N1500

    CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/57 ,  C12N2710/24143 ,  C12N2760/18534

    摘要： An immunization strategy to provide protection against disease caused by infection with a paramyxoviridae virus, specifically respiratory syncytial virus (RSV) and parainfluenza virus, is described. A priming intranasal administration of a recombinant virus expressing at least one RSV or PIV protein or immunogenic sequence there first is made to the host followed by a booster administration of at least one purified RSV or PIV protein or immunogenic fragment thereof, which may be adjuvanted with alum. This immunization strategy provides a safe and effective means of controlling RSV and PIV infections. The strategy leads to a stronger protective immune response than other strategies and to the induction of a more balanced Th-1/Th-2 type response than previously attained. Novel recombinant poxviruses are provided containing nucleic acid encoding a paramyxovirus protein or immunogenic fragment thereof is a non-essential region of the poxvirus genome, specifically NYVAC-F and ALVAC-F, which produce the F glycoprotein of RSV.

    摘要翻译： 描述了针对由副粘病毒病毒，特别是呼吸道合胞病毒（RSV）和副流感病毒感染引起的疾病的免疫策略。 首先向宿主施用表达至少一种RSV或PIV蛋白或免疫原性序列的重组病毒的引发鼻内给药，随后加强施用至少一种纯化的RSV或PIV蛋白或其免疫原性片段，其可以用 明矾。 这种免疫策略为控制RSV和PIV感染提供了安全有效的手段。 该策略导致比其他策略更强的保护性免疫应答，并且诱导比之前达到的更平衡的Th-1 / Th-2型反应。 提供含有编码副粘病毒蛋白的核酸的新型重组痘病毒，或其免疫原性片段是产生RSV的F糖蛋白的痘病毒基因组，特别是NYVAC-F和ALVAC-F的非必需区域。